Immune protection conferred by recombinant MRLC (myosin regulatory light chain) antigen in TiterMax Gold® adjuvant against experimental fasciolosis in rats

详细信息    查看全文

• 作者：Luan C. Henker^a ; Claiton I. Schwertz^a ; Neuber J. Lucca^a ; Manoela M. Piva^a ; Keila C. Prior^b ; Piotr Baska^c ; Luke Norbury^d ; Kamil Januszkiewicz^d ; Diogenes Dezen^b ; Marta M.M.F. Duarte^e ; Rafael N. Moresco^f ; Liana Bertagnolli da Rosa^g ; Ricardo E. Mendes^a ; ^{ricardo.mendes@ifc-concordia.edu.br}
• 关键词：MRLC ; Fasciola hepatica ; Vaccine
• 刊名：Vaccine
• 出版年：2017
• 出版时间：23 January 2017
• 年：2017
• 卷：35
• 期：4
• 页码：663-671
• 全文大小：1878 K
• 卷排序：35

文摘

Fasciola hepatica in an important animal and human pathogen. First experimental trial evaluating Fasciola hepatica MRLC antigen in a rodent model. 51.0% immune protection conferred.